Loading viewer...
annual_report
Format: PDF annual_report
Alnylam Pharmaceuticals reported a transformational 2025 with 81% year-over-year product revenue growth to $2.987 billion, driven by the exceptional launch of AMVUTTRA for ATTR cardiomyopathy and strong performance in rare diseases. The company achieved GAAP profitability for the first time and advanced a robust pipeline including Phase 3 trials for next-generation TTR silencers and cardiovascular therapies.
presentation
annual_report
82 Pages
Kvaerner
CPI Aerostructures 2018 Annual Report
annual_reportannual_report
57 Pages
CPI Aerostructures
annual_report
Daiichi Sankyo
annual_report
eBay
annual_report
Capcom